RecruitingNCT04946721
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study
Sponsor
University of Maryland, Baltimore
Enrollment
150 participants
Start Date
Apr 27, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Evaluate and study the immunologic changes to the ocular surface in cancer patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
- The patient must be able to understand and sign and date the informed consent form approved by the IRB.
Exclusion Criteria3
- Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
- Inability or refusal to provide informed consent.
- History of ocular surgery (except refractive surgery or cataract surgery)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTThe standard care exam and biological specimens' collection
During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04946721
Related Trials
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT0712862832 locations
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
NCT0728438120 locations
An Evaluation of the Safety and Tolerability of Ocular Lubricants
NCT072386994 locations
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT0726451710 locations
A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.
NCT073638241 location